Loading data for CING — first visit, this takes a few seconds.
Cingulate Inc. (CING)
NasdaqCM: CING
· Precio en tiempo real · USD
5.01
-0.19 (-3.65%)
Al cierre: Aug 19, 2026, 11:34 AM
Cingulate Inc. (CING) Stock Price, Analysis & Data
-3.65% (1D)
| Precio de compra | 3.75 |
| Capitalización de mercado | 75.33M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -28.8M |
| Beta | n/a |
| EPS (TTM) | -3.56 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -7 |
| P/B (TTM) | 14.97 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 6.5 |
| Volumen | 72,914 |
| Volumen medio (20D) | 429,253 |
| Abierto | 5.15 |
| Anterior Cerrar | 5.20 |
| Rango del día | 5.01 - 5.25 |
| Rango de 52 semanas | 3.16 - 11.89 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
Industria Biotechnology
Sector Healthcare
IPO Fecha Dec 8, 2021
Empleados 14
Bolsa de Valores NasdaqCM
Símbolo bursátil CING
Sitio web https://www.cingulate.com
Desempeño financiero
En 2025, los ingresos de Cingulate fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -22.45M, un aumento de 35.57%.
Estados financierosSorpresa de resultados
Cingulate ha publicado sus resultados trimestrales en Aug 13, 2026:
